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Abstract
Objective: To determine if blood levels of 25-hydroxyvitamin D (25-D) or its active
metabolite, 1,25-dihydroxyvitamin D (1,25-D), are lower in women at the time of first
diagnosis of breast cancer than in comparable women without breast cancer.
Design: This was a clinic-based case–control study with controls frequency-matched
to cases on race, age, clinic and month of blood drawing.
Setting: University-based breast referral clinics.
Subjects: One hundred and fifty-six women with histologically documented
adenocarcinoma of the breast and 184 breast clinic controls.
Results: There were significant mean differences in 1,25-D levels (pmol ml−1) between
breast cancer cases and controls; white cases had lower 1,25-D levels than white
controls (mean difference 6 SE: −11.08 6 0.76), and black cases had higher 1,25-D
levels than black controls (mean difference 6 SE: 4.54 6 2.14), although the number
of black women in the study was small. After adjustment for age, assay batch, month
of blood draw, clinic and sample storage time, the odds ratio (95% confidence
interval, CI) for lowest relative to highest quartile was 5.2 (95% CI 2.1, 12.8) for white
cases and controls. The association in white women was stronger in women above
the median age of 54 than in younger women, 4.7 (95% CI 2.1, 10.2) vs. 1.5 (95% CI
0.7, 3.0). There were no case–control differences in 25-D levels in either group.
Conclusions: These data are consistent with a protective effect of 1,25-D for breast





The classic function of 1,25-D, the hormonally active
form of vitamin D, is the maintenance of normal levels
of calcium and phosphorus in the blood. However,
recent work has defined a previously unsuspected
involvement of vitamin D in cellular growth and
differentiation1. This recognition has fostered an
interest in the investigation of a possible role for vitamin
D in carcinogenesis2,3. Ecological studies support a
relationship between low levels of sunlight exposure
and incidence of breast cancer (USSR)4,5 and mortality
from breast cancer (USA)6,7. A single case–control study
in Canada, however, failed to demonstrate an associa-
tion between low consumption of vitamin D, as
determined by dietary history, and breast cancer in
women above and below the age of 50 years8. Serum
studies on these women were not available.
The role played by vitamin D in carcinogenesis is
unclear. 1,25-D treatment both inhibits growth and
promotes differentiation in human breast adenocarci-
noma cells in culture irrespective of their sex-steroid
dependence9,10. Further, 1,25-D induces apoptosis in
some cultured breast cancer cells11,12. Finally, vitamin D
has an immunoregulatory function13.
The effects of 1,25-D are regulated primarily by an
intracellular vitamin D receptor (VDR) in a manner
analogous to other steroid hormones14, although
receptor-independent mechanisms may also be impor-
tant15. High affinity VDRs have been reported in
breast cancer cell lines with and without oestrogen
receptors10,16.
There is little clinical information on the effect of
early stage breast cancer on blood levels of the vitamin
D metabolites. One study indicates that early stage
invasive breast cancer itself does not affect blood
levels of 1,25-D17. Nevertheless, it is recognized that
patients with advanced disease and hypercalcaemia of
malignancy often have low circulating concentrations
of 1,25-D and parathyroid hormone (PTH)18,19.
Racial differences in both breast cancer and vitamin D
metabolism have been described. Black and Hispanic
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women with breast cancer have lower overall 5-year
survival rates than white women, even when differences
in stage at diagnosis and differences in treatment are
taken into account20. Studies report racial differences in
vitamin D metabolism and utilization for both blacks
and Hispanics compared to whites21–24, with lower
levels of 25-D and higher levels of 1,25-D and PTH in
minority women. It is unclear what the mechanism for
these differences may be; some investigators interpret
the low levels of 25-D as being due to a lower produc-
tion of vitamin D in more heavily pigmented skin25,26.
There is one published study to date in which no
relationship was found between prediagnostic 1,25-D
levels and breast cancer27. However, the serum levels of
vitamin D were obtained an average of 15 years before
the clinical diagnosis of cancer. The authors noted that
they did not adequately address a possible protective
effect of serum vitamin D at a time more proximal to
clinically evident breast cancer27. Our study was
designed to determine whether blood levels of the
active metabolite of vitamin D, 1,25-D, are lower in
black and white women at the time of first diagnosis of
breast cancer than in comparable women without
breast cancer. A second purpose was to determine
whether levels of the precursor hormone, 25-D, are
related to breast cancer risk, and to describe the
relationship between the two vitamin D metabolites
among these study subjects.
Methods
Source population
Blood samples and interview data were available on
633 subjects who had participated in a previous study
of genetic determinants of breast cancer28. The current
study was approved by the Committee on the
Protection of the Rights of Human Subjects of the
School of Medicine of the University of Carolina,
Chapel Hill. Women with biopsy documented, incident
breast cancer (less than 6 months post-diagnosis, no
chemotherapy) had been recruited from the Duke
University Multidisciplinary Breast Clinic, the Univer-
sity of North Carolina Hospital Breast Clinic and the
Durham Regional Hospital Clinic, over a 15-month
period from April 1990 through June 1991. More than
90% of cases were enrolled into the study within 2
weeks of diagnosis, often prior to the biopsy providing
a definitive diagnosis of breast cancer. Control group
subjects came from these same clinics, but did not have
breast cancer. Each control answered the question-
naire, donated blood, and was found to be free of
breast cancer. The study was restricted to females aged
21 or older. Women were excluded from the study if
there was a current or past diagnosis of epithelial
hyperplasia, with or without atypia. Controls were
frequency-matched to cases on age (within 3 years),
race, clinic and month of blood drawing. A second
control group came from two general medical clinics at
the University of North Carolina and had non-breast-
related complaints. These women were matched to
cases on age (within 3 years) and race and were
enrolled in the study during an 8-week period from
mid-April to mid-June 1991.
There were 215 women with breast cancer; 51 were
excluded because they had been diagnosed more than
6 months before the beginning of study enrollment.
One woman with phylloides tumour was excluded and
blood samples for seven women could not be located
or were not of sufficient quantity for assay, leaving
blood samples from 156 subjects with adenocarcinoma
of the breast for analysis in the case group. There were
samples from 215 control women in the breast referral
clinics; 30 of these subjects were excluded from the
study because they did not meet the frequency-
matching criteria, and one blood sample could not be
located, leaving samples from 184 subjects for analysis
in the breast clinic group. There were 203 subjects in
the second control group; 29 of these women were
excluded because they did not meet the frequency-
matching criteria, and three samples could not be
located, resulting in 171 samples for assay from subjects
in the second group.
Questionnaire
Information on numerous known or suspected risk
factors for breast cancer was collected via a ques-
tionnaire administered during an interview. These data
included race/ethnicity, age, body build, educational
attainment, alcohol and cigarette use, obstetric and
gynaecological history, exogenous sex hormone
exposure, personal and family history and past breast
biopsy and mammography.
Laboratory determinations
The specimens available to us were frozen as whole
blood and we were therefore unable to obtain either
plasma or serum for analysis. Thus we performed a
preliminary validation study in 19 volunteers to
investigate the feasibility of using the archived samples
of frozen, ethylenediamenetetra-acetic acid (EDTA)-
anticoagulated whole blood for the analysis of 25-D and
1,25-D.There was significant correlation between ranks
of the values from whole blood and plasma: rr =0.58,
P , 0.01 for 1,25-D and rr =0.78, P , 0.01 for 25-D.
Briefly, the values of the active metabolite, 1,25-D,
were on average 27% lower when determined in whole
blood than when determined in plasma from volun-
teers. Values for 25-D were 50–60% lower in whole
blood. The lower values in the whole blood assays are
probably related to the diluting effect of the
haemolysed red cells. Levels of 25-D were further
decreased because, unlike the 1,25-D analyses, values
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could not be corrected for individual sample recoveries
with the 25-D assay technique. The coefficient of
variation (CV) for interassay determinations of 1,25-D
was greater in whole blood than in plasma, 14.8%
versus 4.9%, respectively. Similarly, the CV for intra-
assay determinations based on whole blood was greater
than that for plasma, 11.2% versus 6.3%. Interassay CV
for 25-D was higher in whole blood than in plasma,
24.8% versus 17.1%. Intra-assay CV for 25-D was less in
whole blood than in plasma, 6.8% versus 8.1%.
The case–control study blood samples were stored at
−808C from the beginning of collection in 1990 until the
time of assay, an average of 3.99 6 0.52 (mean 6 SD)
years. 1,25-D assays were done with a tritium-based
calf thymus radioreceptor assay kit (INCSTAR, Still-
water, Minnesota) and the 25-D assays with a 125iodine-
based radioimmunoassay kit (INCSTAR, Stillwater,
Minnesota). These assays measure both ergocalciferol
(vitamin D2) and cholecalciferol (vitamin D3). Equal
numbers of samples were randomly selected from the
three groups: cases, control group 1 and control group
2. Thus, each group contributed roughly one-third of
the 40 study samples in each assay batch. Quality
controls provided by INCSTAR and two to four samples
of pooled plasma were included in each batch to
monitor assay validity and reliability. Fourteen per cent
of the analyses had to be redone because of technical
difficulties such as problems with recovery. Laboratory
personnel were blinded to case and control status.
Statistical analysis
We used standard methods for the analysis of case–
control studies29 and employed SAS software for the
statistical analyses30. Univariate distributions of the
exposure variables and the relevant covariates guided
decisions on coding of variables. Potential confounders
were identified with bivariate analyses. We calculated
odds ratios (ORs) using both 2 ×2 tables and
unconditional logistic regression models. We included
the matching variables in multivariate logistic regres-
sion models. The initial analysis considered 1,25-D in
pmol ml−1 as a continuous variable; a second analysis
used quartiles of 1,25-D with cut-off points defined
by the distribution of 1,25-D among subjects in the
relevant control group(s). We evaluated possible
departure from linearity on the logistic scale by
including squared terms in the models, and possible
interactive effects by adding terms for the products of
pairs of variables. P values given are all two-sided.
Results
Subject characteristics
Four hundred and twenty-three (83%) of the study
subjects were non-Hispanic white and 74 (14%) were
black; there were eight Asian American, one native
American and five Hispanic subjects. Women in the
latter three minority categories were excluded from
further analyses because their numbers were too small
to provide meaningful results.
Black subjects were, on average, younger than white
subjects and both black cases and black controls had
higher body mass indices (BMIs) than whites (Table 1).
Both black and white control subjects had character-
istics usually associated with case status: they tended to
have had fewer children and many had a history of
benign breast disease.
We had originally intended to include the second
control group in our breast cancer analyses. However,
subjects in the second control group were not
comparable to the case group or the primary control
group either in month of blood drawing, length of
sample storage time or clinic of origin. For these
reasons, they were dropped from the breast cancer
analyses but were included in the analyses of
seasonality and race (Fig. 1 and Table 2).
Seasonal variability
An analysis of variance among all study subjects (n =
511) indicated that there were significant differences in
the mean levels of 25-D by month of blood drawing
(F11,510 =2.18, P , 0.015; Fig. 1a). Levels were lowest in
the month of February and were highest in the month
of July. By contrast, there were no differences in the
mean levels of 1,25-D according to the month of blood
drawing among all study subjects (F11,510 =0.90, P =
0.54; Fig. 1b). This was also true for groups analysed
separately by race or case or control status (data not
shown).
Assay batch and sample storage
Case sample storage time was shorter than control
group sample storage time by approximately 74 days
(4.06 6 0.68 years vs. 4.26 6 0.36 years, P , 0.01). The
logistic models for risk were adjusted for storage time
with a continuous variable and adjusted for interbatch
variability by an indicator variable for assay batch in
multivariate logistic models.
Vitamin D metabolites
White cases had significantly lower levels of 1,25-D
(pmol ml−1) than white controls; the difference was in
the opposite direction for black subjects although the
number of subjects was smaller. There were no case–
control differences in mean values of 25-D for either
group (Table 2). Looking only at control subjects, the
mean levels of 1,25-D were higher in blacks than in
whites and the mean levels of 25-D were lower in
blacks than in whites (Table 2).
The distributions of both 1,25-D and 25-D had a
slight positive skew among all control subjects; this was
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also true for black and white controls analysed
separately. Normalizing the distributions by taking the
square root did not alter the results of the analyses so
the results presented are those using the untransformed
variables. There was no correlation between levels of
1,25-D and 25-D among all subjects as shown in the
scatterplot of Fig. 2.
Disease status
The level of 1,25-D was related to risk in a linear fashion
(on the logit scale); the level of 25-D was not related to
risk of disease. Table 3 presents the unadjusted
relationship between quartile of 1,25-D and breast
cancer risk. Based on these data we estimate that
women in the lowest quartile had a 3.2-fold increased
risk compared to those in the highest quartile, when all
cases were compared with all non-cases. For white
women the estimated risk of breast cancer was 4.5-fold
(95% CI 2.2, 9.1) for the lowest quartile. Tests for trend
using the Mantel extension test were significant at the
P , 0.001 level for the entire group and the white
subgroup.
Black women did not have the same estimated risk of
breast cancer associated with the lowest quartile of
1,25-D: OR 0.5 (95% CI 0.1, 2.7). A stratified analysis by
race with the median defined by the distribution of
1,25-D in black and white controls (51.6 pmol ml−1)
produced an OR for below median levels for blacks of
1.0 (95% CI 0.4, 2.7) and for whites of 2.2 (95% CI
1.4, 3.4); the Breslow–Day x21df was 2.1, P =0.15,
suggesting possible effect modification by race.
Adjustment for the matching variables, assay batch
and sample storage time increased the estimated risk
for the lowest quartile in white women to 5.3 (95% CI
Table 1 Comparison of selected characteristics by race and disease status
Black subjects White subjects
Case (n =21) Control (n =30) Case (n =131) Control (n =149)
Age, years (mean (SD)) 49.1 (10.9) 50.4 (13.5) 55.0 (12.3) 54.8 (11.9)
BMI, kg m−2 (mean (SD)) 31.1 (7.2) 29.3 (6.2)a 25.5 (5.5)a 24.6 (4.0)
Menarche, years (mean (SD)) 12.5 (1.5) 12.7 (1.3)a 12.7 (1.3)b 12.9 (1.6)
Menopausal status
Pre (no. (%)) 6 (28.6) 10 (33.3) 42 (32.1) 47 (31.5)
Post (no. (%)) 15 (71.4) 20 (66.7) 89 (67.9) 102 (68.5)
Age at menopause, years (mean (SD)) 43.1 (9.1) 43.05 (9.26)a 45.32 (32.1)c 43.4 (8.0)a
Ever pregnant
Yes (no. (%)) 20 (95.2) 24 (80.0) 116 (88.5) 128 (85.9)
No (no. (%)) 1 (4.8) 6 (20.0) 15 (11.5) 21 (14.1)
Parity, no. of live children (mean (SD)) 3.6 (2.5) 2.38 (2.5) 2.5 (1.6) 2.30 (1.0)
Age at first full-term pregnancy, years (mean (SD)) 20.1 (4.8) 22.2 (5.1) 23.2 (4.3) 22.9 (4.2)
Ever use oral contraceptives
Yes (no. (%)) 10 (47.6) 19 (63.3) 70 (53.4) 69 (46.3)
No (no. (%)) 11 (52.4) 11 (36.7) 61 (46.6) 60 (53.7)
Ever use hormone replacement therapy
Yes (no. (%)) 2 (9.5) 8 (26.7)a 53 (40.5) 58 (38.9)a
No (no. (%)) 19 (90.5) 21 (70.0) 78 (59.5) 90 (60.4)
Ever smoke
Yes (no. (%)) 6 (28.6) 13 (43.3) 60 (45.8) 62 (41.6)
No (no. (%)) 15 (71.4) 17 (56.7) 71 (54.2) 87 (58.4)
Drink alcohol
Ever (no. (%)) 7 (33.3) 21 (70.0){** 69 (52.7) 92 (61.7)
Never (no. (%)) 14 (66.7) 9 (30.0) 62 (47.3) 57 (38.3)
Education
High school (no. (%)) 7 (33.3) 0 19 (14.5) 16 (10.7)
High school, some college (no. (%)) 10 (47.6) 18 (60.0)x* 72 (54.9) 80 (53.7)
College graduate þ (no. (%)) 4 (19.1) 12 (40.0) 40 (30.5) 53 (35.6)
Breast cancer in a primary relative
Yes (no. (%)) 1 (4.8) 2 (6.7) 24 (18.3) 30 (20.1)
No (no. (%)) 20 (95.2) 28 (93.3) 107 (81.7) 119 (79.9)
History of benign breast disease
Yes (no. (%)) 4 (19.0) 9 (30.0) 59 (45.0) 89 (59.7)x*
No (no. (%)) 17 (80.9) 21 (70.0) 71 (54.2)a 60 (40.3)
a1 data point missing.
b2 data points missing.
c8 data points missing.
*x2 test (case vs. control), P , 0.05.
{**x2 test (case vs. control), P , 0.01.
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2.1, 13.4) (Table 3). Because of the possibility that more
advanced disease could affect the blood level of 1,25-D,
a subset analysis was carried out, omitting those women
with lymph node metastases at the time of diagnosis
(n =26) from the multivariate logistic regression (Table
3). The estimated adjusted OR for the lowest quartile was
4.0 (95% CI 1.5, 10.8).
We conducted a case–case comparison among white
subjects to examine the relationship between stage of
Fig. 1 Seasonal plot for (a) 25-D and (b) 1,25-D. Results are
mean 6 SEM in nmol ml−1 and pmol ml−1, respectively. The
statistical significance of the seasonal variation is given, as

































































































































































































































































































































Fig. 2 Scatterplot of the relationship between circulating concen-
trations of 1,25-D and 25-D. There was no correlation between
metabolite levels (n =511)
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disease and the level of 1,25-D. There were no
differences in level of 1,25-D between those subjects
with ductal carcinoma in situ (DCIS) and subjects with
invasive ductal carcinoma. Similarly, among women
with invasive ductal carcinoma there was no difference
in 1,25-D levels between women with lymph node
metastases at time of diagnosis and those without
lymph node metastases.
The adjusted estimated risk, OR, associated with low
versus high 1,25-D levels was higher for oestrogen and/
or progesterone receptor-positive breast cancer than
receptor-negative breast cancer, 5.0 (95% CI 2.3, 11.0)
versus 1.1 (95% CI 0.5, 3.0), respectively (Table 4). The
Breslow–Day x21df was 5.9, P =0.02, indicating that
oestrogen/progesterone receptor status may modify
the breast cancer risk associated with low 1,25-D.
Relationship between previously described
risk factors for breast cancer and vitamin D
metabolites
We performed a stratified analysis with white subjects
to investigate possible interactions between 1,25-D and
selected covariates. An interaction was considered
present if the Breslow–Day statistic for homogeneity
of the ORs was significant at the 0.10 level31. The
estimated risk, OR, for breast cancer risk related to low
versus high 1,25-D levels was greater for women above
the age of 54 than for women aged 54 or younger, 4.7
(95% CI 2.1, 10.2) versus 1.5 (95% CI 0.7, 3.0), x21df =
4.7, P =0.03. Adjustment for matching variables, assay
batch, sample storage time and clinic did not
appreciably affect the ORs. There were no differences
in estimated breast cancer risk associated with values of
1,25-D below the median by menopausal status, value
of BMI, level of 25-D, or use of hormone replacement
therapy.
Discussion
The data in this work support the hypothesis that low
levels of the active metabolite of vitamin D, 1,25-D, are
associated with an increased risk of breast cancer. The
estimated OR was greater than ORs previously reported
for other ‘established and probable’ risk factors with the
exception of a family history of breast cancer and a
history of atypical hyperplasia, for both of which ORs of
around 4.0 have been reported32. The vitamin D–breast
cancer relationship was more pronounced in older than
in younger women. Blot’s original geographical
description of breast cancer also suggested such a
Table 3 Odds ratios (95% CI) for the estimated risk of breast cancer associated with quartile of 1,25-D
Quartile of 1,25-D (pmol ml−1)*
No. 1 2 3 4 (ref) P trend
Unadjusted odds ratios
All women 331 3.2 (1.7, 6.0) 1.8 (1.0, 3.4) 1.5 (0.8, 2.9) 1 , 0.001
Black women 51 0.5 (0.1, 2.7) 1.2 (0.2, 5.8) 1.4 (0.3, 6.6) 1 0.40
White women 280 4.5 (2.2, 9.1) 2.2 (1.1, 4.4) 1.8 (0.9, 3.5) 1 , 0.001
Adjusted odds ratios†
White women 280 5.3 (2.1, 13.4) 1.9 (0.8, 4.9) 0.8 (0.3, 2.1) 1 , 0.001
Women with lymph node metastases at time 254 4.0 (1.5, 10.8) 1.4 (0.5, 3.9) 0.5 (0.2, 1.4) 1 0.002
of diagnosis removed from the analysis
* Quartile ranges in pmol ml−1 are based on the distribution of 1,25-D in the respective control group.
Quartiles: 1 2 3 4
All combined < 34.61 34.62–48.41 48.42–63.55 > 63.55
Black < 38.81 38.82–48.41 48.42–71.47 > 71.47
White < 33.61 33.62–48.28 48.29–62.94 > 62.94
† Adjusted for age, assay batch, month of blood draw, clinic and sample storage time.
Table 4 Evaluation of breast cancer risk associated with levels of 1,25-D below the median value by oestrogen
and progesterone receptor status: white cases and controls
1,25-D (pmol ml−1)
Odds ratio Adjusted odds ratio
Group < 53.38 >53.38 (95% CI)* (95%CI)†
Receptor positive‡
Case 44 9 4.8 (2.2, 10.6) 5.0 (2.3, 11.0)
Control 75 74 1 1
Receptor negativex§
Case 11 10 1.1 (0.5, 2.7) 1.1 (0.5, 3.0)
Control 75 74 1 1
* Breslow–Day: x2 1df = 5.9, P =0.02.
† Adjusted for age, clinic and sample storage time.
‡ Oestrogen and/or progesterone receptors present.
§ Neither receptor present.
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relationship7. Breast cancer risk increases with age and
while some studies have indicated that 1,25-D levels fall
with age33, others report no difference in 1,25-D levels
between healthy young and healthy elderly subjects34–37.
Nevertheless, elderly women who are homebound,
whether or not they are receiving supplementation, are
at risk for vitamin D deficiency38.
There may be racial differences in the vitamin D–
breast cancer relationship. Lower levels of 1,25-D did
not appear to be associated with breast cancer among
black subjects, although they were clearly associated
among whites. However, the effect of low 1,25-D was
greater in older women among the white subjects, and
the younger ages of the small sample of black women
in our study may have prevented our seeing this effect
in black subjects. The small number of black women in
the study and the large confidence intervals around the
estimated risks make it premature to draw conclusions
about the association between low 1,25-D and risk of
breast cancer in black women.
Levels of 1,25-D were similar in women with DCIS
and invasive ductal carcinoma; this supports the
assumption that early disease does not affect the
levels of the active metabolite, but rather that
the reduced blood level precedes the onset of breast
cancer. There was no indication of a ‘prognostic effect’;
the magnitude of the estimated breast cancer risk
was similar for subjects with DCIS, invasive ductal
carcinoma without lymph node metastases, and
invasive ductal carcinoma with lymph node metastases.
Nevertheless, advanced disease with bone metastases
and hypercalcaemia has been associated with
depressed levels of 1,25-D19.
The use of lysed whole blood rather than the
preferred substrate of serum or plasma for analysis of
the vitamin D metabolites was a potential weakness of
this study. However, the validation study confirmed
that the assay could be done validly and reliably with
the substrate at hand, and the direction of the results
with regard to racial differences in both 1,25-D and
25-D is consistent with earlier work22–26. Furthermore,
the maintenance of 1,25-D with age in healthy subjects
is consistent with the findings of other researchers34–37.
The seasonal variability detected for 25-D has also been
reported by other investigators, as has the lack of
seasonal variability for 1,25-D33; this agreement with
previous work further supports the validity of our data.
We did not have data on dietary intake of vitamin D,
calcium, phosphorus, vitamin supplementation or sun-
light exposure. Nevertheless, the blood level of 25-D is
generally felt to be an accurate measure of vitamin D
adequacy19. Since the majority of circulating hormone
is produced by the action of ultraviolet B light on the
skin, blood measurements of 25-D should reflect
availability of vitamin D from all exogenous and
endogenous sources. The lack of a difference in the
blood level of 25-D between cases and controls
supports the probability that both groups had adequate
physiological amounts of the precursor hormone.
However, selective decreases in dietary calcium and/
or phosphorus among the controls or selective
increases among the cases relative to the controls,
while unlikely, could have affected the 1,25-D levels39.
These were unusually similar cases and controls with
respect to the usual breast cancer risk factors such as
age at menarche, age at first pregnancy, BMI and age at
menopause. This was probably a function of the
selection process; the cases and controls were
perceived by themselves and others to be at high risk
for breast cancer and had attended specialized breast
referral clinics. If vitamin D acts through pathways
independent of the traditional risk factors, controlling
for these traditional risk factors could increase the
power of our study to detect 1,25-D effects40.
Previous studies have failed to detect a relationship
between the precursor and the active metabolite41. Our
results are similar in this regard. This observation is
consistent with the possibility that vitamin D insuffi-
ciency per se is not related to disease, but rather there
may be a mechanism involving inadequacy in the
conversion of the precursor metabolite to the active
metabolite33,42. The renal enzyme 1a-hydroxylase that
catalyses this conversion would be a likely site for such
a mechanism. Activity of this enzyme may be
genetically based. There is evidence that activity of
the enzyme may decrease with age, thus placing
older women at increased risk, particularly if their
sources of vitamin D are inadequate42. Alternative
mechanisms might relate to the vitamin D receptor and
its levels in the breast43, or to specific genetic
polymorphisms of the receptor, which may result in
functional differences44,45.
Our data indicate that lower levels of 1,25-D are
associated with an increased risk of breast cancer in
white women. However, the vitamin D–breast cancer
relationship in black and other minority women
remains to be described. The data are consistent with
the possibility that mechanisms other than vitamin D
deficiency are responsible for the association between
lower levels of 1,25-D and the risk of breast cancer. The
findings need to be verified in a prospective study, as
these issues have major implications for supplementa-
tion strategies. If protective effects of 1,25-D are shown,
chemoprevention and/or chemotherapy using vitamin
D analogues—synthetic compounds with effects on
cellular growth and differentiation with minimized
effect on calcium metabolism46–48—would be an
important area of investigation.
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